Amgen Research Munich GmbH


Products/services: Drug Development, Antibody, Immune Therapy, Oncology

    • Short facts
      • Manufacturer
    • Year founded 1993
    • 122 Employees (site)
    • Turnover: 10m - <50m EUR
    Amgen Research Munich GmbH
    Hanauer Str. 1
    80992 München
    Munich, Federal State Capital / Upper Bavaria
    +49 89 149 096-0
    +49 89 149 096-2000
    Language skills
    Location Map
    Key to Bavaria Map
  • Core competencies

    Micromet puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform: BiTETM ('Bispecific T cell engagers'), a unique drug format that leverages the outstanding cytotoxic potential of T cells to precisely eliminate pathogenic cells. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drug candidates. The Company has attracted both top-tier life science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc., and Serono.

    Key sectors / sub-sectors
    • Biotechnology: Prophylactic drug development
    • Biotechnology: Therapeutic drug development
    NACE industries
    • Other research and experimental development on natural sciences and engineering 72.19
    Certifications / awards

    not available

    Sales markets - target industries
    not available
    Sales markets - target countries
    not available
    Cooperation offers
    not available